Cytomx analysts
WebApr 6, 2024 · Find the latest CytomX Therapeutics, Inc. (CTMX) stock analysis from Seeking Alpha’s top analysts: exclusive research and insights from bulls and bears. … WebApr 13, 2024 · We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst …
Cytomx analysts
Did you know?
WebApr 14, 2024 · The company has a market cap of £24.70 billion, a P/E ratio of 3,198.81, a PEG ratio of 1.90 and a beta of 0.51. Experian has a 12-month low of GBX 2,242 ($27.76) and a 12-month high of GBX 3,160 ... WebApr 13, 2024 · This is a summary of recent ratings and recommmendations for CytomX Therapeutics and Stoke Therapeutics, as provided by MarketBeat. CytomX Therapeutics currently has a consensus price target of $3.17, indicating a potential upside of 94.57%. Stoke Therapeutics has a consensus price target of $24.57, indicating a potential upside …
WebApr 14, 2024 · CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Rating of “Hold” from Analysts Globe Life (NYSE:GL) PT Lowered to $129.00 Morgan Stanley Lowers ICL Group (NYSE:ICL) Price Target to $7.50 WebMar 31, 2024 · CytomX Therapeutics, Inc. (NASDAQ:CTMX– Get Rating) – Stock analysts at HC Wainwright raised their Q1 2024 earnings per share estimates for CytomX Therapeutics in a report released on...
WebThe latest price target for . CytomX Therapeutics (NASDAQ: CTMX) was reported by Mizuho on March 28, 2024.The analyst firm set a price target for $2.00 expecting CTMX to rise to within 12 months ... WebApr 14, 2024 · CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Rating) has received an average rating of “Hold” from the twelve analysts that are covering the firm, Marketbeat …
WebJul 7, 2024 · Analysts have provided the following ratings for CytomX Therapeutics (NASDAQ:CTMX) within the last quarter: These 8 analysts have an average price target …
WebMar 31, 2024 · CytomX Therapeutics, Inc. (CTMX) Stock Price Today, Quote & News Seeking Alpha CTMX CytomX Therapeutics, Inc. Stock Price & Overview 3.73K … portascanner airtight 520WebMar 29, 2024 · So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also expecting losses per share to increase. Check out our latest analysis for CytomX Therapeutics . NasdaqGS:CTMX Earnings and Revenue Growth March 29th 2024 portas motherboardWebApr 14, 2024 · CytomX Therapeutics, Inc. (NASDAQ:CTMX– Get Rating) has received an average rating of “Hold” from the twelve analysts that are covering the firm, Marketbeatreports. One equities research... irvine coffee shopsWebCytomX is a clinical-stage, oncology-focused biopharmaceutical company dedicated to destroying cancer differently. By pioneering a novel class of conditionally activated biologics, powered by its Probody® technology platform, CytomX’s goal is to transcend the limits of current cancer treatments. CytomX’s robust and differentiated pipeline ... irvine commercial insurance brokers coventryWebOct 8, 2015 · Based in South San Francisco, CA, CytomX Therapeutics (NASDAQ: CTMX) scheduled a $97 million IPO on Nasdaq with a market capitalization of $524 million at a price range midpoint of $15 for ... portas enigmas hogwarts legacyWebApr 9, 2024 · 8 Analysts CTMX Stock Overview CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. About the company Risk Analysis Negative shareholders equity Currently unprofitable and not forecast to become profitable over the next 3 years See All Risk Checks My Notes portascreen shower guardWebApr 6, 2024 · Find the latest CytomX Therapeutics, Inc. (CTMX) stock analysis from Seeking Alpha’s top analysts: exclusive research and insights from bulls and bears. portascanner watertight